Clinical Trial Update: Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating once-daily rivaroxaban to prevent cardiovascular events in patients with nonvalvular atrial fibrillation undergoing cardioversion; the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• Xarelto (rivaroxaban)

Snippet

Sponsor: Bayer | Conditions: Atrial Fibrillation | Phase 3 | Status: COMPLETED | Results posted: 2015-02-03